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Background: We assessed laboratory data related to mortality in hemodialysis (HD) patients. In our preliminary
study, we examined all of the data for HD outpatients in our facility according to whether the patient had survived.
A statistically significant difference was observed for the reticulocyte count, which has not previously been
considered a prognostic factor. We subsequently verified the relationship between all-cause and cardiovascular
mortality and reticulocyte count.
Methods: We retrospectively analyzed the data of 358 hemodialysis outpatients who were followed up for an
average of 41.4 months. The patients were divided into quartiles according to the reticulocyte count levels.
Results: Higher reticulocyte counts were associated with female gender, an increase in interdialytic body weight
gain, serum erythropoietin level, white blood cell count, and increased levels of lactate dehydrogenase, inorganic
phosphorus, non-high-density lipoprotein, and glucose. As compared with patients in the lowest quartile, those in
the highest quartile showed significantly higher adjusted hazard ratios (HRs) for all-cause (HR 3.12; 95% confidence
interval (CI) 1.26 to 7.74) and cardiovascular (HR 4.93; 95% CI 1.24 to 19.56) mortality. For every 104 cells/μL increment in
the reticulocyte count, the adjusted HRs for all-cause and cardiovascular mortality were 1.33 (95% CI 1.17 to 1.51) and
1.38 (95% CI 1.17 to 1.63), respectively. The association of reticulocyte count with all-cause and cardiovascular mortality
was independent of other prognostic factors. Stepwise multivariable Cox analysis indicated that only age showed
stronger association with all-cause mortality than reticulocyte count. Regarding cardiovascular mortality, reticulocyte
count was found as the strongest progenitor. We also examined the relationship between the reticulocyte count and
the temporal hemoglobin trend (a slope of changes in hemoglobin levels over time). A statistically significant negative
correlation was found.
Conclusions: Higher reticulocyte counts were associated with higher mortality. We speculate that this result reflects
tissue hypoxia, which results in a higher erythropoietin level, or a compensatory erythropoietic response due to the
accelerated clearance of erythrocytes. Prospective studies are warranted to confirm our findings.
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To improve the prognosis of chronic maintenance
hemodialysis (HD) patients, it is important to identify
simple and inexpensive prognostic factors. In our
preliminary analysis, we examined data from a total
of 1,814,698 HD outpatients. These data were obtained
from January 4, 1999 to December 26, 2003. We divided
patients into two groups depending on whether they had
survived until the end of 2003. Student’s t tests were per-
formed for each comparison. In addition to the established
prognostic factors, we found that the mean reticulocyte
count was significantly higher in the non-survivor group.
The means +/− standard deviations (SDs) of the reticulo-
cyte count were 46.4 × 103 +/− 0.2 × 103 cells (sample
count 8732) in the survivor group and 52.4 × 103 +/−
0.2 × 103 cells in the non-survivor group (sample count
1111) p = 6.09 E−15.
Reticulocytes are young red blood cells that develop
from erythroblasts and circulate in the bloodstream for
approximately 1–4 days before maturing into erythro-
cytes [1]. These cells provide a real-time assessment of
the functional state of erythropoiesis [2] and are thus
useful in both diagnosing anemias and monitoring the
bone marrow response to therapy [3]. While reticulocyte
count is widely measured in routine laboratory work,
the clinical significance of the reticulocyte count in pa-
tients on chronic maintenance HD has yet to be clearly
delineated [4].
In this study, we conducted a retrospective single-
center analysis of the data of 358 patients under chronic
maintenance HD to examine the association of reticulo-
cyte counts with all-cause/cardiovascular mortality and
hemoglobin trends (Hb trend).
Methods
Study design and patients
This is a retrospective observational study of 358 pa-
tients under regular maintenance hemodialysis at Hidaka
Hospital. Patients were excluded from the study, when
they had required hospitalization during 3 months prior
to enrollment due to hematologic disorder, active bleed-
ing, acute cardiovascular events, infectious diseases, or
other comorbid conditions such as blood access troubles
or traffic accidents. No patient had received chemother-
apy for malignancy during the 3 months prior to enroll-
ment. In addition, we did not include patients who had
obvious inflammatory symptoms at the beginning of the
enrollment period. The observation period was from
January 2000 to July 2005, which was 5 years before dar-
bepoetin therapy was introduced in our facility. The
mean ± SD of the age of the cohort was 60.2 ± 12.6 years
(range, 29 to 89 years), and the patients had been on
maintenance hemodialysis for 8.5 ± 7.0 years, on average
(range, 0.3 to 27.9 years). During the follow-up period,52 patients were censored at departure to another dialy-
sis unit. The mean follow-up period was 41.4 ±
16.6 months (range, 0.5 to 53.3 months).
The demographic and medical data were obtained
from the medical records and interviews with the pa-
tients. The demographic data included age, gender, dur-
ation of dialysis, primary cause of renal failure,
interdialysis weight gain, body mass index (BMI), dry
weight, systolic blood pressure, diastolic blood pressure,
vascular disease history, and smoking history (ever ver-
sus never). Vascular disease history was defined as a
history of hospitalization due to coronary heart disease,
heart failure, arrhythmia, valvular disease, aortic
aneurysm, peripheral arterial disease, atrial septal de-
fect, deep vein thrombosis, or cerebrovascular accident,
including cerebral bleeding or infarction. The medica-
tion exposure data included the use of angiotensin-
converting enzyme inhibitors (ACE-Is) or angiotensin
receptor blockers (ARBs), the use of intravenous iron
injections during the week prior to enrollment, and the
average weekly dose of recombinant human erythropoi-
etin (rHuEPO) at 1, 2, or 4 weeks prior to the observa-
tion period. None of the patients was receiving
darbepoetin or continuous erythropoietin receptor acti-
vator (CERA) during the observation period in our co-
hort. Medical data were obtained from the records for
the week prior to the enrollment. The doses of rHuEPO
and iron were adjusted to maintain the hemoglobin
level at approximately 10.0 g/dl, according to the dos-
age column of the Insurance Price List [5].
Blood samples were obtained on the first day of the
week before the start of the dialysis sessions undertaken
at 2-day intervals and were subjected to determination
for Hb, reticulocyte count, white blood cell count
(WBC), platelet count (Plt), transferrin saturation
(TSAT), ferritin, albumin (Alb), lactate dehydrogenase
(LDH), blood urea nitrogen (BUN), creatinine (Cr),
phosphorus inorganic (iP), total cholesterol, triglyceride,
high-density-lipoprotein, blood sugar, C reactive protein
(CRP), and erythropoietin (EPO). Determination for
most of these parameters was undertaken as a part of
the routine clinical work. The data obtained at a single
time point within a week before enrollment were used
for subsequent entire analysis. Concentrations of BUN
were measured before and after a single dialysis session
at enrollment to determine KT/V according to the pro-
cedure of Shinzato et al. [6]. The reticulocyte count was
measured according to the method of Brecher [7].
Hb trend was obtained to determine the slope of the
changes in the Hb levels over time, a best-fit (ordinary
least squares) line of Hb over time until 2 weeks or
6 months after the start of the observation period was
plotted for each subject; the temporal trend in Hb was
represented by the slope of this line [8].
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Data are expressed as mean ± SD. We used χ2 or
ANOVA to test for differences in the categorical or con-
tinuous factors, respectively, among the four quartiles of
patients divided according to the reticulocyte count. The
primary outcome was all-cause and cardiovascular mor-
tality. Cardiovascular death was defined as death from
coronary heart disease, heart failure, peripheral artery
disease, cardiomyopathy, arrhythmia, cardiac arrest,
valvular disease, infective endocarditis, rupture of aortic
aneurysm, mesenteric artery occlusion, or cerebral
bleeding. Survival curves were estimated by the Kaplan-
Meier method, followed by a log-rank test. Univariate
and multivariate analyses were conducted using the Cox
proportional hazards model. Statistical significance was
defined as p < 0.05. The models of association for all-
cause mortality and death due to cardiovascular disease
were built using a forward stepwise multivariate Cox
modeling with p < 0.05 set as the inclusion criterion. The
20 candidate parameters were evaluated to identify asso-
ciations between variables and outcome. The parameters
tested were age, sex, diabetic nephropathy (DMN), dur-
ation of dialysis, interdialysis body weight gain, vascular
disease history, use of ACE-I or ARB, systolic blood
pressure, diastolic blood pressure, weekly dose of
rHuEPO for a week before the enrollment (1w rHuEPO),
Hb, WBC, Plt, iP, Cr, Alb, CRP, ferritin, TSAT, and re-
ticulocyte count. The statistical contribution of each
variable to the association of the outcome was assessed
by the χ2 statistic. Pearson correlations were used to test
the relationships among the reticulocyte count, temporal
trend of Hb, and dose of rHuEPO.
Results
Patient characteristics
We retrospectively analyzed the data of a total of 358
patients undergoing regular hemodialysis at Hidaka
Hospital. The observation period extended from January
2000 to July 2005. During a mean follow-up of
41.4 months (0.5 to 53.3 months), 82 deaths were
documented (heart failure n = 19, coronary heart disease
n = 14, infection n = 12, malignant disease n = 9, periph-
eral artery disease n = 3, cardiomyopathy n = 4, gastro-
intestinal tract bleeding n = 4, cerebral bleeding n = 3,
infective endocarditis n = 2, valvular disease n = 2,
arrhythmia n = 2, cardiac arrest n = 2, rupture of aortic
aneurysm n = 1, mesenteric artery occlusion n = 1, and mis-
cellaneous n = 4), among which 53 were cardiovascular-
related deaths.
Patients were divided into quartiles according to the re-
ticulocyte counts. Table 1 shows the baseline characteris-
tics of all the patients and of the patients in each
reticulocyte count quartile. Higher reticulocyte counts
were associated with female gender (p = 0.01), interdialysisbody weight gain (p = 0.02), and a lower frequency of the
use of ACE-I or ARB (p < 0.01). Meanwhile, age, duration
of dialysis, blood pressure, history of smoking, weekly dose
of rHuEPO, and use of iron injections were not correlated
with the reticulocyte count.
As for the laboratory parameters, the serum Hb values
were not significantly correlated with the reticulocyte
counts. Patients with higher reticulocyte counts were
more likely to have decreased TSAT, Hb trend (2 weeks
and 6 months) and increase of such parameters as the
serum EPO, WBC, LDH, BUN, iP, total cholesterol, tri-
glyceride, non-high-density lipoprotein (non-HDL), and
glucose.Association of the reticulocyte count with all-cause and
cardiovascular mortality
Crude survival was determined using Kaplan-Meier ana-
lysis with the log-rank test. The risk for all-cause death
differed significantly among the reticulocyte count quar-
tiles (log-rank test χ2 = 28.34, p < 0.001; Fig. 1a). In uni-
variate Cox proportional hazard model, the all-cause
mortality rate was highest in the highest quartile, and
there was a survival gradient across quartiles (Table 2).
After adjustments for background covariates, the hazard
ratio (HR) for all-cause mortality in the highest versus
the lowest quartile of reticulocyte count remained sig-
nificantly high at 4.37 (95% confidence interval (CI) 1.94
to 9.84) (model 1 in Table 2). Additional adjustment for
background and other prognostic factors Hb, WBC, Plt,
TSAT, ferritin, iP, Cr, Alb, and CRP partially attenuated
this estimate (HR 3.12; 95% CI 1.26 to 7.74), but the dif-
ference remained significant. The increase in mortality
was in a relatively linear fashion. In the univariate ana-
lysis, the HR was significantly high for reticulocyte count
increments of 1 × 104/μL (HR 1.29; 95% CI 1.18 to 1.42;
p < 0.001). The effect of reticulocyte count on the sur-
vival remained statistically significant after adjustments
(model 1, HR 1.37, 95% CI 1.23 to 1.53; model 2, HR
1.33, 95% CI 1.17 to 1.51).
Significant increase of the cardiovascular death rates
was also observed from the lowest to the highest
reticulocyte count quartiles (log-rank test, χ2 = 20.36,
p < 0.001) (Fig. 1b). The HR for cardiovascular death
in the highest quartiles of reticulocyte count was sig-
nificantly higher as compared with that in the lowest
quartile at 5.67 (95% CI 1.94 to 16.59) (Table 2). The
highest quartile of reticulocyte count, compared with
the lowest, was significantly associated with the risk of
cardiovascular death after adjustments (models 1 and
2). The effect of every 104 cells/μL increment in the
reticulocyte count on the cardiovascular death also
remained statistically significant after adjustments
(models 1 and 2 in Table 2)
Table 1 Baseline patient characteristics
Characteristics Reticulocyte count p
All Patients Q1 Q2 Q3 Q4 ANOVA or χ2
No. of patients 358 89 90 89 90
Range of reticulocyte count (103/μL) 9.3 to 147.9 ≤30.1 30.2 to 39.4 39.6 to 53.6 ≤53.7
Demographics
Age (year) 60.2 (12.6) 60.4 (13.8) 60.4 (12.7) 61.0 (12.6) 59.1 (11.4) 0.78
Male gender (%) 67.3 78.7 70.0 64.0 56.7 0.01
Duration of dialysis (year) 8.5 (7.0) 7.9 (6.2) 8.8 (6.6) 8.8 (7.6) 8.7 (7.4) 0.80
Cause of renal failure
Diabetes mellitus (%) 29.9 23.6 27.8 33.7 34.4 0.34
BMI 20.6 (3.0) 20.0 (2.4) 20.6 (3.0) 20.6 (2.8) 21.1 (3.5) 0.09
Dry weight (kg) 53.1 (10.3) 53.0 (9.0) 53.3 (12.1) 52.2 (9.1) 53.7 (10.7) 0.80
Interdialysis weight gain (%) 5.6 (1.9) 5.1 (1.9) 5.6 (1.9) 5.4 (2.0) 6.0 (1.7) 0.02
Smoking history (%) 44.9 48.8 42.9 45.3 42.5 0.84
Vascular disease history (%) 47.8 41.6 42.2 53.9 53.3 0.18
Medication
ACE or ARB (%) 30.7 40.4 38.1 25.6 18.9 <0.01
Injection of Fe (%) 25.1 22.5 30.0 25.8 22.2 0.60
1w rHuEPO/week (IU/w) 3694 (3077) 3396 (2874) 4321 (2949) 3584 (3281) 3508 (3154) 0.19
2w rHuEPO/week (IU/w) 3727 (3079) 3459 (2906) 4415 (2971) 3576 (3255) 3496 (3079) 0.13
4w rHuEPO/week (IU/w) 3752 (3063) 3550 (2912) 4339 (2900) 3628 (3259) 3521 (3142) 0.25
Systolic blood pressure (mmHg) 151.9 (23.6) 154.8 (20.9) 155.5 (22.4) 146.8 (25.6) 150.33 (24.5) 0.05
Diastolic blood pressure (mmHg) 78.4 (11.6) 79.4 (12.1) 80.4 (11.1) 76.8 (10.0) 76.9 (13.0) 0.11
Laboratory parameters
Reticulocyte count (103/μL) 43.4 (19.4) 22.5 (5.1) 35.1 (2.7) 45.8 (4.0) 69.6 (16.1) <0.001
Hemoglobin (g/dL) 9.9 (1.1) 9.8 (1.2) 9.9 (1.0) 9.8 (1.0) 10.1 (1.2) 0.20
Mean corpuscular volume (fL) 97.8 (6.8) 97.2 (6.3) 98.9 (6.2) 97.9 (7.0) 97.0 (7.7) 0.22
White cell count (103/μL) 6.1 (2.1) 5.4 (1.5) 6.0 (1.8) 6.2 (2.2) 6.9 (2.5) <0.001
Platelet count (103/μL) 185 (67) 172 (53) 182 (58) 187 (65) 199 (87) 0.06
Iron (μg/dL) 57.2 (23.3) 58.9 (25.9) 60.3 (25.0) 57.2 (20.0) 52.6 (21.4) 0.13
TSAT (%) 21.9 (10.1) 24.1 (11.8) 23.0 (10.1) 21.8 (9.1) 18.9 (8.5) <0.01
Ferritin (ng/mL) 101 (135) 116 (167) 94 (107) 108 (160) 85 (92) 0.43
AST (U/L) 15.9 (8.8) 15.5 (6.4) 14.8 (6.0) 17.2 (12.6) 16.1 (8.5) 0.32
ALT (U/L) 14.2 (10.3) 13.6 (7.3) 13.7 (8.0) 15.4 (15.9) 14.0 (7.7) 0.62
Alkaline phosphatase (U/L) 251 (101) 253 (115) 249 (78) 246 (96) 255 (114) 0.94
Total bilirubin (mg/dL) 0.20 (0.09) 0.21 (0.10) 0.19 (0.06) 0.20 (0.10) 0.20 (0.09) 0.60
Lactate dehydrogenase (U/L) 335 (81) 323 (70) 322 (66) 342 (83) 353 (98) 0.03
Blood urea nitrogen (mg/dL) 77.4 (17.4) 70.1 (14.5) 80.3 (18.1) 79.1 (18.2) 80.1 (16.7) <0.001
Creatinine (mg/dL) 11.7 (2.8) 11.5 (3.1) 12.0 (2.6) 11.5 (2.7) 11.8 (2.7) 0.63
Corrected calcium (mg/dL) 9.30 (0.88) 9.25 (0.84) 9.19 (0.92) 9.28 (0.88) 9.48 (0.87) 0.14
Phosphorus inorganic (mg/dL) 5.95 (1.50) 5.49 (1.42) 5.90 (1.33) 5.91 (1.56) 6.43 (1.53) <0.001
Parathyroid hormone intact (pg/mL) 212 (191) 212 (206) 229 (172) 198 (292) 210 (184) 0.75
Albumin (g/dL) 3.72 (0.36) 3.71 (0.35) 3.80 (0.36) 3.68 (0.76) 3.68 (0.35) 0.07
Total protein (g/dL) 6.46 (0.51) 6.43 (0.49) 6.49 (0.50) 6.43 (0.58) 6.49 (0.50) 0.71
Glucose (mg/dL) 135 (62) 122 (40) 128 (47) 141 (72) 149 (78) 0.01
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Table 1 Baseline patient characteristics (Continued)
Total cholesterol (mg/dL) 157 (34) 147 (31) 154 (33) 162 (31) 165 (36) <0.01
High-density lipoprotein (mg/dL) 45 (14) 43 (12) 46 (14) 46 (15) 45 (15) 0.43
Triglyceride (mg/dL) 117 (68) 97 (48) 107 (62) 120 (62) 143 (87) <0.001
Non-HDL (mg/dL) 112.1 (32.3) 104.2 (29.8) 108.1 (31.1) 116.4 (31.3) 119.9 (34.9) <0.01
C-reactive protein (mg/dL) 0.57 (1.33) 0.41 (0.76) 0.45 (1.16) 0.56 (1.23) 0.86 (1.88) 0.11
Serum erythropoietin (U/L) 16.2 (22.8) 11.0 (9.0) 12.0 (8.0) 14.7 (12.0) 26.6 (40.4) <0.001
Kt/V 1.23 (0.25) 1.19 (0.24) 1.26 (0.27) 1.24 (0.23) 1.23 (0.24) 0.41
Hb trend 0.5 mo (g/dL/week) n = 353 −0.02 (0.39) 0.01 (0.06) 0.08 (0.37) −0.03 (0.31) −0.12 (0.44) 0.01
Hb trend 6 mo (g/dL/week) n = 338 0.01 (0.07) 0.03 (0.06) 0.01 (0.06) 0.00 (0.05) −0.01 (0.09) <0.01
Results are displayed as mean (standard deviation). Patients were quartiled according to reticulocyte count. Q1, ≤30.1 × 103 cells/μL; Q2, 30.2 to 39.4 × 103 cells/μL;
Q3, 39.6 to 53.6 × 103 cells/μL; and Q4, ≥53.7 × 103 cells/μL
Note: BMI body mass index, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, rHuEPO recombinant human erythropoietin, 1w rHuEPO/week
the dose of rHuEPO per week for 1 week prior to enrollment, 2w rHuEPO/week the average dose of rHuEPO per week for 2 weeks prior to enrollment, 4w rHuEPO/
week the average dose of rHuEPO per week for 4 weeks prior to enrollment, TSAT transferrin saturation, AST aspartate aminotransferase, ALT alanine aminotransferase,
non-HDL non-high-density lipoprotein, Hb trend 0.5 mo hemoglobin trend untill 0.5 month, Hb tred 6 mo hemoglobin trend untill 6 months
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cardiovascular mortality. For each outcome, Cox propor-
tional hazards models were built using a forward step-
wise procedure. The variables are listed in order of their
statistical strength of association with outcome, as repre-
sented by the χ2 statistic. Reticulocyte count showed the
second most powerful association with death from any
cause, with χ2 of 29.85. In this model, increased reticulo-
cyte count showed among the most significant overall
correlations of outcome, showing stronger statistical as-
sociation than presence/absence of DMN, CRP, iP, and
vascular disease history. Only age showed stronger inde-
pendent association with outcomes. In our model for
cardiovascular death, reticulocyte count showed the
strongest association (χ2 = 25.38).
Correlation between the reticulocyte count and temporal
trend of Hb
We next examined whether higher reticulocyte counts
translated into a rise of the Hb levels during the following
period. To determine the slope of the change in the Hb
levels over time, we evaluated Hb trend until 2 weeks and
6 months after the start of the observation period. Among
the 358 subjects, 8 died within the first 6 months of enroll-
ment, before the trend in Hb levels could be determined.
Hb concentrations were distributed in a very narrow range;
the mean Hb trend was −0.02 +/− 0.39 g/dL/week at
2 weeks and 0.01 +/− 0.07 g/dL/week at 6 months. As
shown in Fig. 2a, b, the reticulocyte count was nega-
tively correlated with the temporal trend of Hb at
2 weeks (r = −0.20, p < 0.001, n = 358) as well as
6 months (r = −0.21, p < 0.001, n = 338).
Dose of rHuEPO and mortality
We examined all subjects in the cohort, including those
who had received (n = 281) and those who had notreceived (n = 73) 1 week of treatment with rHuEPO
(four patients’ data were not available). We re-examined
the prognostic impact of the reticulocyte count by separ-
ately analyzing subgroups of patients according to
whether they had received rHuEPO. The prognostic im-
pact of a high reticulocyte count with respect to the all-
cause mortality remained significant not only in patients
who had been treated with rHuEPO (HR per 104 cells/
μL 1.33; 95% CI 1.20 to 1.47) but also in those who had
not been treated with rHuEPO (HR per 104 cells/μL
1.28; 95% CI 1.03 to 1.59). Furthermore, the HR for all-
cause mortality in the subgroup that had been treated
with rHuEPO was not attenuated by an adjustment for
the rHuEPO dose (HR 1.34; 95% CI 1.20 to 1.48). These
data suggested that the association of the reticulocyte
count with mortality was not dependent on the dose of
rHuEPO.
Reproducibility of the association between reticulocyte
count and all-cause and cardiovascular mortality
We also evaluated the association between the reticulo-
cyte count and mortality at different time points. A total
of 203 patients whose reticulocyte count data were avail-
able at 1 year prior to enrollment were divided into
quartiles according to the reticulocyte count. A total of
32 deaths were documented, among which 25 were due
to a cardiovascular cause. The range of each group was
as follows: pQ1 ≤ 31.5 × 103 cells/μL, pQ2 (31.5 × 1033
cells/μL to 42.1 × 103 cells/μL), pQ3 (42.2 × 103 cells/μL
to 54.2 × 103 cells/μL), and pQ4 ≥ 54.4 × 103 cells/μL.
Survival curves were estimated via the Kaplan-Meier
method, followed by the log-rank test. The risk for all-
cause and cardiovascular death differed significantly
among the reticulocyte count quartiles (all-cause death
log-rank test χ2 = 9.479, p = 0.02; Fig. 3a/cardiovascular
death log-rank test χ2 = 9.914, p = 0.02; Fig. 3b). In the
Fig. 1 Kaplan-Meier survival curves according to reticulocyte count quartiles. Patients were divided into quartiles according to the reticulocyte
count. Q1, ≤30.1 × 103 cells/μL; Q2, 30.2 to 39.4 × 103 cells/μL; Q3, 39.6 to 53.6 × 103 cells/μL; and Q4, ≥53.7 × 103 cells/μL. a Overall survival;
p < 0.001 as determined by a log-rank test conducted to compare the four groups. b Patients who had not died from cardiovascular causes;
p < 0.001 according to a log-rank test conducted to compare the four groups
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significantly higher for reticulocyte count increments of
1 × 104/μL for both all-cause mortality (HR 1.35; 95% CI
1.14 to 1.60; p < 0.001) and cardiovascular mortality (HR
1.41; 95% I 1.14 to 1.73; p < 0.001). Thus, our findings
revealed that the reticulocyte count was related to mor-
tality at 1 year prior to enrollment.Discussion
One striking finding of this retrospective study was that
the reticulocyte count showed very strong correlation
with the all-cause and cardiovascular mortality in
patients on maintenance HD. Multivariate analysis
revealed that reticulocyte count was associated with all-
cause and cardiovascular mortality, even after adjusting
Table 2 Adjusted association between quartile of reticulocyte count and mortality
Unadjusted Model 1 Model 2
HR (95% CI) p HR (95% CI) p HR (95% CI) p
All-cause mortality
Q1 1 (Reference) <0.001† 1 (Reference) <0.001† 1 (Reference) 0.003†
Q2 1.23 (0.52 to 2.93) 0.95 (0.37 to 2.49) 0.71 (0.26 to 1.96)
Q3 3.06 (1.43 to 6.52) 2.24 (0.98 to 5.16) 1.94 (0.83 to 4.58)
Q4 4.37 (2.10 to 9.10) 4.37 (1.94 to 9.84) 3.12 (1.26 to 7.74)
per 104 cells/μL 1.29 (1.18 to 1.42) <0.001 1.37 (1.23 to 1.53) <0.001 1.33 (1.17 to 1.51) <0.001
Cardiovascular mortality
Q1 1 (Reference) <0.001† 1 (Reference) 0.005† 1 (Reference) 0.03†
Q2 1.86 (0.56 to 6.19) 1.91 (0.47 to 7.62) 1.59 (0.37 to 6.79)
Q3 5.59 (1.92 to 16.27) 4.97 (1.41 to 17.46) 4.18 (1.14 to 15.25)
Q4 5.67 (1.94 to 16.59) 6.57 (1.85 to 23.34) 4.93 (1.24 to 19.56)
per 104 cells/μL 1.28 (1.14 to 1.43) <0.001 1.37 (1.19 to 1.56) <0.001 1.38 (1.17 to 1.63) <0.001
Patients were quartiled according to reticulocyte count. Q1, ≤30.1 × 103 cells/μL; Q2, 30.2 to 39.4 × 103 cells/μL; Q3, 39.6 to 53.6 × 103 cells/μL; Q4, ≥53.7 × 103 cells.
Model 1 is adjusted for age, sex, diabetic nephropathy, duration of dialysis, interdialysis weight gain, smoking status, vascular disease history, use of angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers, systolic blood pressure, diastolic blood pressure, and weekly dose of recombinant human
erythropoietin. Model 2 is adjusted for model 1 covariates and hemoglobin, white blood cell, platelet count, transferrin saturation, ferritin, phosphorus
inorganic, creatinine, albumin, and C-reactive protein
Note: HR hazard ratio, CI confidence interval
†p for linear trend
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patients, such as age, history of DMN, preexisting vascu-
lar disease, weekly dose of rHuEPO, Hb, WBC count,
serum Alb, Cr, iP, or CRP. The correlation between all-
cause mortality and reticulocyte count showed stronger
statistical relation than the presence/absence of DMN,
CRP, iP, and vascular disease history. Only age showed
stronger independent association with outcomes. InTable 3 Correlation models for all-cause and cardiovascular mortalit
Variables HR
All-cause mortality
Age (per 1 year) 1.08
Reticulocyte count (per 104cells/μL) 1.36
Diabetic nephropathy yes vs no 3.19
C-reactive protein (per 1 mg/dL) 1.28
Phosphorus inorganic (per 1 mg/dL) 1.24
Vascular disease yes vs no 1.77
Cardiovascular mortality
Reticulocyte count (per 104 cells/μL) 1.40
Diabetic nephropathy yes vs no 4.62
C-reactive protein (per 1 mg/dL) 1.38
Age (per 1 year) 1.08
Diastolic blood presure (per 1 mmHg) 0.97
Stepwise, multivariate Cox proportional regression models were developed using ca
variables are age, sex, diabetic nephropathy, duration of dialysis, interdialysis weight g
angiotensin receptor blockers, systolic blood pressure, diastolic blood pressure, weekly
platelet count, transferrin saturation, ferritin, phosphorus inorganic, creatinine, albumin
Note: HR hazard ratio, CI confidence intervaladdition, the strongest correlation was observed between
cardiovascular mortality and reticulocyte count. There is
only one previously reported study in the literature, by
Cantaro et al., in which the prognostic value of the re-
ticulocyte count was investigated [9]. This study, in
which the data of 117 HD patients were analyzed for a
period of 12 months and the reticulocyte count tended
to be higher in the deceased group, however, failed toy based on forward stepwise Cox proportional hazard regression
95% CI χ2 p
1.06 to 1.11 40.00 <0.001
1.22 to 1.51 29.85 <0.001
1.98 to 5.13 22.65 <0.001
1.14 to 1.44 16.21 <0.001
1.03 to 1.46 5.18 0.02
1.06 to 2.95 4.84 0.03
1.23 to 1.60 25.38 <0.001
2.51 to 8.50 24.20 <0.001
1.21 to 1.58 22.87 <0.001
1.04 to 1.10 21.15 <0.001
0.95 to 0.99 6.56 0.01
ndidate variables to predict all-cause and cardiovascular mortality. Candidate
ain, vascular disease history, use of angiotensin-converting enzyme inhibitors or
dose of recombinant human erythropoietin, hemoglobin, white blood cell,
, C-reactive protein, and reticulocyte count. Inclusion criterion is p < 0.05
Fig. 2 Correlation of the reticulocyte counts with the Hb trends at
2 weeks and 6 months. To derive the temporal trend in hemoglobin, a
best-fit (ordinary least squares) line of hemoglobin over time was plotted
for each subject: the slope of this line represented the temporal trend of
the hemoglobin level. a Correlation of the reticulocyte count with the
Hb trend at 2 weeks (n= 358). The correlation coefficient was r =−0.20,
p< 0.001. b Correlation of the reticulocyte count with the Hb trend at
6 months (n= 338). The correlation coefficient was r=−0.21, p< 0.001
Takagi et al. Renal Replacement Therapy  (2017) 3:4 Page 8 of 11show any significant correlation between the reticulocyte
count and mortality. This discrepant result from our
present study may be attributable to differences in the
sample size, observation period, and/or methodology be-
tween the two studies.
The second important finding of this study was that
reticulocyte counts showed a strong positive association
with female gender, interdialytic body weight gain, and
levels of serum EPO, WBC, LDH, iP, non-HDL, and glu-
cose. EPO levels were assessed at intervals of more than
72 h from the last injection of rHuEPO; therefore, the
impact of rHuEPO might have been small. Several
studies have reported an increased level of plasma EPO
in patients with heart failure, which was correlated to a
more severe outcome [10–13]. Meanwhile, female
gender, inflammation, hyperphosphatemia, hypergly-
cemia, and dyslipidemia were identified as potential risk
factors of microvascular dysfunction [14–16]. In post-
menopausal women, microvascular dysfunction has beenlinked with adverse outcomes, such as Syndrome X
[14]. Recently, Shah et al. reported that global coron-
ary flow reserve, which is defined as the ratio of stress
to rest for absolute myocardial blood flow and is a re-
liable indicator of coronary microvascular function,
may provide independent and incremental risk stratifi-
cation for all-cause and cardiovascular mortality in pa-
tients with dialysis-dependent end-stage renal disease
(ESRD) [17].
The third finding is that high reticulocyte counts were as-
sociated with negative Hb trends. The mean value of Hb at
the time of enrollment was not significantly different among
the four groups, and the slope of the change in Hb level
over half of 1 year was very gentle (0.01 +/− 0.07 g/dL/w);
however, the reticulocyte count was wide-ranging
(9.27 × 103/μL to 146.9 × 103/μL). We theorize that those
patients who need a high reticulocyte count to maintain
the target Hb level may experience a poorer prognosis.
Given these findings, we would like to present two hy-
potheses for the relationship between high reticulocyte
count and poor outcome. The first is that the reticulo-
cyte count could be a sensitive marker of tissue hypoxia.
Reductions in tissue oxygen tension due to microvascu-
lar dysfunction would be expected to lead to the activa-
tion of hypoxia-inducible transcription factors [15],
which in turn might initiate the production of EPO.
EPO increases reticulocyte release from the bone
marrow and therefore prolongs the maturation time of
circulating reticulocytes; this is likely the reason for find-
ings showing a high reticulocyte count [18]. Even HD
patients might produce EPO in response to chronic
hypoxia. Indeed, Brookhart et al. suspected that ESRD
patients who lived at high altitudes could increase en-
dogenous EPO production [19].
The second hypothesis is that reticulocytosis is a result
of the accelerated clearance of red blood cells (RBCs). A
study showed that the RBC lifespan was significantly and
negatively correlated with the erythropoiesis-stimulating
agent (ESA) requirement of the patients [20]. Our findings
imply that the reticulocytosis found in patients with a
poorer prognosis may reflect the compensatory increase
of erythropoiesis against the accelerated clearance of
circulating RBCs as result of occult bleeding or impair-
ment of RBC survival, including hemolysis [21], or in-
creased eryptosis (apoptotic erythrocyte death) [22, 23].
Oxidative stress [24] and mechanical pressure [25] might
play some roles.
There were some limitations to our study; first, it was
a retrospective study without a pre-specified hypothesis;
therefore, data on some important parameters were lack-
ing. Although we speculated that hemolysis or eryptosis
might have been the reason for the increased reticulo-
cyte counts, we did not measure either the serum hapto-
globin, phosphatidylserine-positive erythrocyte counts,
Fig. 3 Kaplan-Meier survival curves according to reticulocyte count quartiles at 1 year prior to enrollment. Patients were divided into quartiles
according to their reticulocyte count: pQ1, ≤31.5 × 103 cells/μL; pQ2, 31.5 × 103 cells/μL to 42.1 × 103 cells/μL; pQ3, 42.2 × 103 cells/μL to 54.2 × 103
cells/μL; and pQ4, ≥54.4 × 103 cells/μL. a Overall survival; p = 0.02 as determined by a log-rank test conducted to compare the four groups. b Patients
who had not died from cardiovascular causes; p = 0.02 according to a log-rank test conducted to compare the four groups
Takagi et al. Renal Replacement Therapy  (2017) 3:4 Page 9 of 11or spleen size. Second, our patients were treated with
short-acting ESAs, and it would be unreasonable to ex-
trapolate our findings to patients treated with darbepoe-
tin or CERA. Finally, the average Hb level in our study
subjects was lower than the target Hb level recom-
mended in the guidelines published in Europe and the
USA [26, 27], although this level was within the average
range in Japan [28].Conclusions
In summary, our findings demonstrated that higher re-
ticulocyte counts in hemodialysis patients are associated
with a higher mortality rate. The exact mechanisms
underlying the association of the reticulocyte count
with the mortality are still unknown. We propose that
the increased reticulocyte count is a result of tissue
hypoxia or is a compensatory mechanism to maintain
Takagi et al. Renal Replacement Therapy  (2017) 3:4 Page 10 of 11the target Hb concentration. Further studies are neces-
sary to explore the mechanisms underlying the close
association between the reticulocyte count and mortal-
ity in HD patients.
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